A 12 week Phase Ib Randomized Investigator and Subject-Blinded Placebo Controlled Repeat-dose Study of LLF580

This is a phase 1b, placebo-controlled, double-blind, randomized trial to evaluate the effect of 300 mg LLF580 (the study drug) given as subcutaneous injections in obese subjects with moderately elevated triglycerides. All subjects must have a body mass index (BMI) of 30 to 45 kg/m^2 inclusive, with ethnic adjustment of over 27.5 kg/m^2 (inclusive) for Asian individuals. All subjects must have fasting triglycerides between 150-500 mg/dL at screening to participate. Subjects will have 10 outpatient visits, and 2 overnight stays (day -1 to day 1, and day 84 to day 85) over the course of 6 months. Procedures include blood draws, physicals, ECGs, vitals, questionnaires, collection of urine and saliva, MRIs and ultrasounds. Subjects receive a 300 mg subcutaneous injection of blinded LLF580 or placebo on days 1, 28, & 56 (3 doses total)

You may be eligible for this study if you meet the following criteria:

• Conditions:
  healthy Volunteers, healthy subjects, Healthy, Healthy volunteer, triglycerides - high, High, healthy, healthy, -overweight
• Age: Between 18 Years - 65 Years
• Gender: All